Coloplast A/S banner

Coloplast A/S
CSE:COLO B

Watchlist Manager
Coloplast A/S Logo
Coloplast A/S
CSE:COLO B
Watchlist
Price: 421.5 DKK -1.56% Market Closed
Market Cap: kr94.9B

EV/EBIT

15.2
Current
45%
Cheaper
vs 3-y average of 27.4

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
15.2
=
Enterprise Value
kr128.3B
/
EBIT
kr7.6B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
15.2
=
Enterprise Value
kr128.3B
/
EBIT
kr7.6B

Valuation Scenarios

Coloplast A/S is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (27.4), the stock would be worth kr761.89 (81% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-10%
Maximum Upside
+88%
Average Upside
40%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 15.2 kr421.5
0%
3-Year Average 27.4 kr761.89
+81%
5-Year Average 28.4 kr791.47
+88%
Industry Average 15.5 kr430.14
+2%
Country Average 13.6 kr378.16
-10%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
kr128.3B
/
Jan 2026
kr7.6B
=
15.2
Current
kr128.3B
/
Sep 2026
kr7.9B
=
16.2
Forward
kr128.3B
/
Sep 2027
kr8.7B
=
14.8
Forward
kr128.3B
/
Sep 2028
kr9.4B
=
13.7
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
DK
Coloplast A/S
CSE:COLO B
96.5B DKK 15.2 24
US
Medline Inc
NASDAQ:MDLN
62B USD 0 0
JP
Hoya Corp
TSE:7741
9.7T JPY 33.7 38.7
CH
Alcon AG
SIX:ALC
30.1B CHF 28.2 37.7
US
Align Technology Inc
NASDAQ:ALGN
14B USD 20.5 34.1
UK
ConvaTec Group PLC
LSE:CTEC
4.5B GBP 18.6 34.3
CA
Bausch + Lomb Corp
NYSE:BLCO
5.7B USD 54.9 -15.7
KR
HLB Inc
KOSDAQ:028300
8T KRW -77.2 -36.4
JP
Asahi Intecc Co Ltd
TSE:7747
868.9B JPY 31.5 49.1
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.4B USD 18 22.9
CN
Intco Medical Technology Co Ltd
SZSE:300677
35.8B CNY 31.5 21.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Coloplast A/S
CSE:COLO B
Average EV/EBIT: 28
15.2
7%
2.2
US
M
Medline Inc
NASDAQ:MDLN
Not Available
18%
N/A
JP
Hoya Corp
TSE:7741
33.7
N/A N/A
CH
Alcon AG
SIX:ALC
28.2
26%
1.1
US
Align Technology Inc
NASDAQ:ALGN
20.5
21%
1
UK
ConvaTec Group PLC
LSE:CTEC
18.6
21%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
54.9
72%
0.8
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -77.2 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
31.5
N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
18
30%
0.6
CN
Intco Medical Technology Co Ltd
SZSE:300677
31.5
24%
1.3
P/E Multiple
Earnings Growth PEG
DK
Coloplast A/S
CSE:COLO B
Average P/E: 32.8
24
21%
1.1
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
38.7
15%
2.6
CH
Alcon AG
SIX:ALC
37.7
32%
1.2
US
Align Technology Inc
NASDAQ:ALGN
34.1
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
34.3
41%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.7 N/A N/A
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.4 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
49.1
40%
1.2
US
Lantheus Holdings Inc
NASDAQ:LNTH
22.9
30%
0.8
CN
Intco Medical Technology Co Ltd
SZSE:300677
21.4
12%
1.8

Market Distribution

In line with most companies in Denmark
Percentile
61st
Based on 367 companies
61st percentile
15.2
Low
0.8 — 6.6
Typical Range
6.6 — 19.5
High
19.5 —
Distribution Statistics
Denmark
Min 0.8
30th Percentile 6.6
Median 13.6
70th Percentile 19.5
Max 473.6

Coloplast A/S
Glance View

Coloplast A/S, headquartered in Humlebæk, Denmark, has a storied history that dates back to 1954 when a nurse, Elise Sørensen, identified a crucial need in the healthcare sector. Her sister had undergone ostomy surgery, and the lack of appropriate post-operative care products inspired Sørensen to design the world’s first adhesive ostomy bag. This innovation laid the groundwork for Coloplast's trajectory in the healthcare industry. Today, the company has expanded its focus to include ostomy care, continence care, wound and skin care, and interventional urology. With a commitment to improving patients' quality of life, Coloplast has become a leader in designing and manufacturing products that not only highlight practicality but also embody comfort and discretion. Coloplast generates revenue through a business model that emphasizes product innovation and direct engagement with healthcare providers and patients. The company invests significantly in research and development to improve and widen its product offerings continuously. It operates globally, distributing its products directly and via partnerships with hospitals, clinics, and healthcare professionals. By maintaining an attentive approach to user experience and incorporating customer feedback into its development processes, Coloplast ensures its portfolio aligns with the actual needs of its users. This user-centered strategy not only enhances customer loyalty but also fortifies the company’s market position, driving its financial success.

COLO B Intrinsic Value
623.95 DKK
Undervaluation 32%
Intrinsic Value
Price kr421.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett